- October 28, 2019
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Greenhouse Gas Emissions Reduction Targets Earn Science Based Targets (SBT) Initiative Certification
Taiho Pharmaceutical Co., Ltd. announced today that its greenhouse gas (GHG) emissions reduction targets have been certified by the Science Based Targets (SBT) Initiative.
The SBT initiative is a collaborative effort between the nongovernmental organization CDP, the United Nations Global Compact (UNGC), the World Resources Institute (WRI), and the World Wildlife Fund for Nature (WWF) for achieving the Paris Agreement-mandated objective of limiting the average global temperature rise to below 2 degrees Celsius. It certifies the CO2 emission reduction targets of companies that are in line with emissions reduction scenarios based on scientific facts.
Certified targets of Taiho Pharmaceutical are listed below.
CO2-reduction targets
・Reduce GHG emissions (Scope 1 + 2) 30% by 2030 from 2017 base year.
・Reduce GHG emissions (Scope 3) 20% by 2030 from 2017 base year.
Scope 1: Direct emissions from in-house fuel use and industrial processes
Scope 2: Indirect emissions from use of electricity associated with purchased electricity/heat
Scope 3: Other indirect emissions such as from supplier and customer activities
In order to attain these new targets, Taiho Pharmaceutical is taking steps such as optimization of energy use and introduction of renewable energy. Taiho Pharmaceutical will also continue to minimize GHG emissions throughout its value chain as part of ongoing efforts to contribute to the realization of a sustainable society.
Information in this news release was current as of the original release date.
Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.